Crescent Biopharma(CBIO)
$14.76+0.84 (+6.00%)
CBIO
Crescent Biopharma financials statements
$14.76
At close:+0.84 (+6.00%)
Want to see CBIO full AI Analyst Report?
Crescent Biopharma (CBIO) Ratios
1,027 Followers
Crescent Biopharma Ratios
CBIO's free cash flow for Q2 2026 was $-19.48M. For the 2026 fiscal year, CBIO's free cash flow was decreased by $-13.00K and operating cash flow was $-19.46M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.56 | 3.62 | 6.41 | 5.71 | 7.68 |
| Quick Ratio | 6.56 | 3.62 | 6.41 | 5.71 | 7.68 |
| Cash Ratio | 5.91 | 3.62 | 6.11 | 5.39 | 7.63 |
| Solvency Ratio | -4.13 | -0.95 | -5.32 | -5.23 | -4.96 |
| Operating Cash Flow Ratio | -1.98 | -3.23 | -5.10 | -5.23 | -4.86 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 199.37M | $ -16.29M | $ 36.89M | $ 41.83M | $ 78.05M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 1.05 | 0.02 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.01 | -2.42 | 0.02 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | 0.01 | 1.70 | 0.02 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 1.70 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.18 | -2.30 | 1.18 | 1.21 | 1.16 |
| Debt Service Coverage Ratio | -69.42 | -51.85 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -69.85 | -58.57 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.37 | 1.97 | 0.01 | 0.02 | 0.04 |
| Net Debt to EBITDA | 1.41 | -0.06 | 1.05 | 0.99 | 1.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -1381.01% | 0.00% | -392746.56% | -63203.84% | -5470.69% |
| EBITDA Margin | -1380.24% | 0.00% | -391213.55% | -62927.65% | -5447.87% |
| Operating Profit Margin | -1407.52% | 0.00% | -392752.93% | -63204.43% | -5470.69% |
| Pretax Profit Margin | -1401.16% | 0.00% | -368987.83% | -62251.15% | -5468.98% |
| Net Profit Margin | -1419.61% | 0.00% | -368994.20% | -62251.74% | -5468.98% |
| Continuous Operations Profit Margin | -1419.61% | 0.00% | -368987.83% | -62251.15% | -5468.98% |
| Net Income Per EBT | 101.32% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 99.55% | 97.25% | 93.95% | 98.49% | 99.97% |
| Return on Assets (ROA) | -64.06% | -136.24% | -81.43% | -90.11% | -67.23% |
| Return on Equity (ROE) | -75.83% | 313.48% | -96.06% | -108.76% | -77.73% |
| Return on Capital Employed (ROCE) | -74.74% | -191.89% | -102.06% | -110.42% | -76.88% |
| Return on Invested Capital (ROIC) | -74.58% | -191.89% | -100.13% | -108.11% | -75.96% |
| Return on Tangible Assets | -64.06% | -136.24% | -81.43% | -90.11% | -67.23% |
| Earnings Yield | -124.64% | -9.99% | -0.25% | -0.29% | -0.86% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.60 | 0.00 | 0.06 | 0.52 | 861.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 4.68 | 0.00 | 0.01 | 0.10 | 0.60 |
| Asset Turnover | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.10 | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash Conversion Cycle | 605.86 | 0.00 | 6417.43 | 700.88 | 0.42 |
| Days of Sales Outstanding | 605.86 | 0.00 | 6417.43 | 700.88 | 0.42 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 605.86 | 0.00 | 6417.43 | 700.88 | 0.42 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.87 | -1.59 | -0.55 | -0.88 | -1.12 |
| Free Cash Flow Per Share | -13.87 | -1.60 | -0.55 | -0.89 | -1.12 |
| Dividend Paid and CapEx Coverage Ratio | -0.98 | -3118.54 | -1630.36 | -551.81 | -3847.25 |
| Capital Expenditure Coverage Ratio | -0.98 | -3118.54 | -1630.36 | -551.81 | -3847.25 |
| Operating Cash Flow Coverage Ratio | -43.51 | -0.83 | -43.15 | -50.58 | -29.94 |
| Operating Cash Flow to Sales Ratio | -6.60 | 0.00 | -3487.99 | -619.43 | -49.57 |
| Free Cash Flow Yield | -116.96% | -6.41% | -0.23% | -0.29% | -0.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.80 | -17.79 | -405.12 | -340.92 | -116.81 |
| Price-to-Sales (P/S) Ratio | 11.39 | 0.00 | 1494882.17 | 212225.94 | 6388.58 |
| Price-to-Book (P/B) Ratio | 0.61 | -31.37 | 389.15 | 370.77 | 90.80 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.86 | -15.61 | -428.32 | -341.99 | -128.85 |
| Price-to-Operating Cash Flow Ratio | -1.73 | -15.61 | -428.58 | -342.61 | -128.88 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.13 | 11.63 | 12.33 | -11.89 |
| Enterprise Value Multiple | 0.59 | -11.05 | -381.07 | -336.26 | -115.87 |
| Enterprise Value | -88.04M | 488.27M | 14.91B | 15.87B | 7.32B |
| EV to EBITDA | 0.59 | -11.05 | -381.07 | -336.26 | -115.87 |
| EV to Sales | -8.12 | 0.00 | 1490783.73 | 211599.91 | 6312.41 |
| EV to Free Cash Flow | 0.61 | -15.70 | -427.14 | -340.98 | -127.31 |
| EV to Operating Cash Flow | 1.23 | -15.70 | -427.40 | -341.60 | -127.34 |
| Tangible Book Value Per Share | 19.49 | -0.79 | 0.61 | 0.82 | 1.59 |
| Shareholders’ Equity Per Share | 19.49 | -0.79 | 0.61 | 0.82 | 1.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.04 | 0.00 | 0.00 | 0.00 | 0.02 |
| Net Income Per Share | -14.78 | -2.49 | -0.58 | -0.89 | -1.23 |
| Tax Burden | 1.01 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.10 | 0.94 | 0.98 | 1.00 |
| Research & Development to Revenue | 12.73 | 0.00 | 2007.17 | 378.55 | 40.95 |
| SG&A to Revenue | 2.34 | 0.00 | 1921.30 | 254.49 | 14.76 |
| Stock-Based Compensation to Revenue | 1.23 | 0.00 | 356.05 | 51.43 | 5.25 |
| Income Quality | 0.46 | 0.82 | 0.95 | 1.00 | 0.91 |
Currency in USD
